These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1092 related articles for article (PubMed ID: 26408403)
41. Programmed Death-Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Temporal Bone Squamous Cell Carcinoma. Hongo T; Kuga R; Miyazaki M; Komune N; Nakano T; Yamamoto H; Koike K; Sato K; Kogo R; Nabeshima K; Oda Y; Nakagawa T Laryngoscope; 2021 Dec; 131(12):2674-2683. PubMed ID: 34143491 [TBL] [Abstract][Full Text] [Related]
42. Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. Oguejiofor K; Galletta-Williams H; Dovedi SJ; Roberts DL; Stern PL; West CM Oncotarget; 2017 Feb; 8(9):14416-14427. PubMed ID: 28122336 [TBL] [Abstract][Full Text] [Related]
43. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics. Karpathiou G; Casteillo F; Giroult JB; Forest F; Fournel P; Monaya A; Froudarakis M; Dumollard JM; Prades JM; Peoc'h M Oncotarget; 2017 Mar; 8(12):19310-19322. PubMed ID: 28038471 [TBL] [Abstract][Full Text] [Related]
44. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas. Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153 [TBL] [Abstract][Full Text] [Related]
45. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer. Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495 [TBL] [Abstract][Full Text] [Related]
46. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer. Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673 [TBL] [Abstract][Full Text] [Related]
47. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796 [TBL] [Abstract][Full Text] [Related]
48. CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. Zhu Y; Li M; Mu D; Kong L; Zhang J; Zhao F; Li Z; Liu X; Bo C; Yu J Oncotarget; 2016 Nov; 7(44):71455-71465. PubMed ID: 27683115 [TBL] [Abstract][Full Text] [Related]
49. Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. Feng Y; Shen J; Gao Y; Liao Y; Cote G; Choy E; Chebib I; Mankin H; Hornicek F; Duan Z Oncotarget; 2015 May; 6(13):11139-49. PubMed ID: 25871477 [TBL] [Abstract][Full Text] [Related]
50. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Wimberly H; Brown JR; Schalper K; Haack H; Silver MR; Nixon C; Bossuyt V; Pusztai L; Lannin DR; Rimm DL Cancer Immunol Res; 2015 Apr; 3(4):326-32. PubMed ID: 25527356 [TBL] [Abstract][Full Text] [Related]
51. Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharygeal, and Hypopharyngeal Cancer. Birtalan E; Danos K; Gurbi B; Brauswetter D; Halasz J; Kalocsane Piurko V; Acs B; Antal B; Mihalyi R; Pato A; Fent Z; Polony G; Timar J; Tamas L Appl Immunohistochem Mol Morphol; 2018 Aug; 26(7):e79-e85. PubMed ID: 29271789 [TBL] [Abstract][Full Text] [Related]
52. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254 [TBL] [Abstract][Full Text] [Related]
53. Prognostic Impact of Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma Patients. Zhang D; Tang D; Heng Y; Zhu XK; Zhou L; Tao L; Lu LM Laryngoscope; 2021 Apr; 131(4):E1249-E1255. PubMed ID: 33107987 [TBL] [Abstract][Full Text] [Related]